Calgenex was acquired for 22 million shares of restricted common stock.
Jeff Roman, CEO and president of PanGenex, said: “Completing the acquisition of Calgenex allows us to aggressively begin marketing our proprietary nutraceutical product line through the internet, physician referrals and other retail platforms.”